Literature DB >> 35726027

DRESS characteristics according to the causative medication.

A Chaabane1, H Ben Romdhane1, N Ben Fadhel1, N Ben Fredj1, H Ammar1, N Boughattas1, Z Chadly1, K Aouam2.   

Abstract

BACKGROUND: To date, no study has identified a clear relationship between drug and a specific clinical presentation of DRESS.
OBJECTIVES: To investigate the particularities of DRESS and analyze the variation of DRESS pattern according to culprit drugs.
METHODS: We analyzed cases of DRESS notified to the Department of Clinical Pharmacology at the University Hospital of Monastir over a 15-year period. The statistical study was performed using the comparative and multivariate analysis.
RESULTS: DRESS was mostly induced by anticonvulsive agents (27%) followed by allopurinol (26.3%) and antibiotics (24%): For anticonvulsive agents, the occurrence of lymphadenopathy was higher, renal involvement was rare and mild, and positive skin tests were more frequent. The allopurinol group was associated with the patient's older age and a lower incidence of lymphadenopathy and kidney injury. For antibiotics, eosinophilia rate was lower, time to recovery was shorter, and RegiSCAR score was low. The multivariate analysis showed a link of allopurinol with severe renal impairment, antibiotics with short latency period and low RegiSCAR score, and anticonvulsants with high propensity of positive skin test.
CONCLUSION: We report the largest African and south Mediterranean cohort of DRESS and evaluated the usefulness of skin tests in identifying the culprit drug. The prominent finding was that latency period and renal involvement may independently differ according to culprit drugs.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  DRESS; Hypersensitivity; Pharmacovigilance; Skin tests

Mesh:

Substances:

Year:  2022        PMID: 35726027     DOI: 10.1007/s00228-022-03353-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   3.064


  25 in total

Review 1.  Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019.

Authors:  Tetsuo Shiohara; Yoshiko Mizukawa
Journal:  Allergol Int       Date:  2019-04-16       Impact factor: 5.836

2.  Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study.

Authors:  Angèle Soria; Claire Bernier; Gwenaelle Veyrac; Annick Barbaud; Etienne Puymirat; Brigitte Milpied
Journal:  J Am Acad Dermatol       Date:  2019-09-25       Impact factor: 11.527

3.  Prevalence, risk factors, and mortality outcome in the drug reaction with eosinophilia and systemic symptoms patients with cardiac involvement.

Authors:  Julphat Intarasupht; Anchisa Kanchanomai; Wuttirak Leelasattakul; Thoranis Chantrarat; Artit Nakakes; Waraporn Tiyanon
Journal:  Int J Dermatol       Date:  2018-08-11       Impact factor: 2.736

4.  Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk.

Authors:  N H Shear; S P Spielberg
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

5.  Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?

Authors:  H Peyrière; O Dereure; H Breton; P Demoly; M Cociglio; J-P Blayac; D Hillaire-Buys
Journal:  Br J Dermatol       Date:  2006-08       Impact factor: 9.302

Review 6.  Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

Authors:  H Bocquet; M Bagot; J C Roujeau
Journal:  Semin Cutan Med Surg       Date:  1996-12

7.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module.

Authors:  Anna R Wolfson; Li Zhou; Yu Li; Neelam A Phadke; Ohn A Chow; Kimberly G Blumenthal
Journal:  J Allergy Clin Immunol Pract       Date:  2018-08-31

Review 8.  Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.

Authors:  Chun-Bing Chen; Ming-Ying Wu; Chau Yee Ng; Chun-Wei Lu; Jennifer Wu; Pei-Han Kao; Chan-Keng Yang; Meng-Ting Peng; Chen-Yang Huang; Wen-Cheng Chang; Rosaline Chung-Yee Hui; Chih-Hsun Yang; Shun-Fa Yang; Wen-Hung Chung; Shih-Chi Su
Journal:  Cancer Manag Res       Date:  2018-05-17       Impact factor: 3.989

9.  Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review.

Authors:  Pahnwat Tonya Taweesedt; Charles W Nordstrom; Jessica Stoeckel; Igor Dumic
Journal:  Biomed Res Int       Date:  2019-09-24       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.